15.3 Hypertensive Emergency & Urgency Management

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

15.3 Hypertensive Emergency & Urgency Management

Key Takeaways Explain This Topic AI

Severe blood pressure elevation is defined as systolic BP ≥180 mm Hg and/or diastolic BP ≥120 mm Hg; the absolute distinction between hypertensive emergency and urgency depends entirely on the presence or absence of acute, life-threatening target organ damage, not the numerical blood pressure value alone.

Hypertensive urgency (severe BP elevation without acute end-organ injury) should be managed in the ambulatory outpatient setting with oral agents (amlodipine, labetalol, captopril, or clonidine) and gradual reduction over 24 to 48 hours; sublingual nifedipine and rapid IV agents are strictly contraindicated in hypertensive urgency due to the risk of precipitous hypotension, cerebral infarction, and myocardial necrosis.

Hypertensive emergency requires immediate ICU admission, continuous intra-arterial blood pressure monitoring, and titratable intravenous antihypertensive infusions; standard reduction targets a maximum 20% to 25% reduction in mean arterial pressure (MAP) within the first hour, followed by reduction toward 160/100 mm Hg over the next 2 to 6 hours, and gradual normalization over 24 to 48 hours.

In acute aortic dissection, standard gradual MAP reduction is abandoned: systolic BP must be lowered rapidly to <120 mm Hg and heart rate to <60 beats/min within 20 minutes; an intravenous beta-blocker (esmolol or labetalol) MUST be administered BEFORE vasodilators (nicardipine or nitroprusside) to prevent reflex tachycardia and increased aortic shear stress (dP/dt).

In acute ischemic stroke, permissive hypertension is observed to maintain cerebral penumbral perfusion: BP is not treated unless it exceeds 220/120 mm Hg in patients not eligible for reperfusion; if IV thrombolysis (tPA/TNK) or mechanical thrombectomy is planned, BP must be carefully lowered to <185/110 mm Hg prior to thrombolysis and maintained <180/105 mm Hg for at least 24 hours post-infusion.

Last updated: September 2026

Definitions, Diagnostic Triage & Target Organ Damage

Severe blood pressure elevation is defined clinically by a systolic blood pressure ≥180 mm Hg and/or diastolic blood pressure ≥120 mm Hg . The critical determinant that guides clinical triage and immediate management is NOT the absolute numerical blood pressure reading, but the presence or absence of acute, ongoing, life-threatening target organ damage (TOD) . SEVERE BLOOD PRESSURE ELEVATION

• (Systolic ≥180 mm Hg and/or Diastolic ≥120 mm Hg)
• │
• ┌────────────────────┴────────────────────┐
• ▼ ▼
• ┌─────────────────────────────┐ ┌─────────────────────────────┐
• │ HYPERTENSIVE URGENCY │ │ HYPERTENSIVE EMERGENCY │
• │ NO Target Organ Damage │ │ ACUTE Target Organ Damage │
• ├─────────────────────────────┤ ├─────────────────────────────┤
• │ • Asymptomatic or mild │ │ • Neurologic, Cardiac, │
• │ headache, epistaxis │ │ Aortic, Renal, Obstetric │
• │ • Ambulatory Outpatient │ │ • Immediate ICU Admission │
• │ • ORAL Medications Only │ │ • CONTINUOUS IV Infusions │
• │ • Gradual reduction over │ │ • Intra-arterial A-line │
• │ 24 to 48 hours │ │ • Rapid, controlled MAP │
• │ • AVOID precipitous drops │ │ reduction by 20-25% │
• │ • Sublingual Nifedipine │ │ • Disease-specific targets │
• │ STRICTLY PROHIBITED │ │ (Aortic, Stroke, Eclampsia│
• └─────────────────────────────┘ └─────────────────────────────┘
• Clinical Spectrum of Acute Target Organ Damage

Clinicians must systematically evaluate five major organ systems for acute injury:

Neurological Damage :

Hypertensive Encephalopathy : Acute syndrome characterized by severe global headache, nausea, projectile vomiting, confusion, lethargy, visual blurriness, seizures, and bilateral optic disc papilledema. Reversible Posterior Leukoencephalopathy Syndrome ( PRES ) with subcortical vasogenic edema is frequently observed on brain MRI.

Acute Ischemic Stroke : Focal neurological deficits (facial droop, hemiparesis, dysarthria, aphasia).

Acute Intracranial Hemorrhage (ICH) / Subarachnoid Hemorrhage (SAH) : Sudden "thunderclap" headache, meningismus, coma, or rapid neurological deterioration.

Cardiovascular Damage :

Acute Aortic Dissection (Stanford Type A or B) : Sudden onset of excruciating, sharp or "tearing" substernal chest and interscapular back pain, asymmetric peripheral pulses, blood pressure discrepancy >20 mm Hg between arms, or new aortic regurgitation murmur.

Acute Coronary Syndrome (ACS) : Ischemic chest pressure, ST-segment elevations or depressions, or acute cardiac troponin elevation.

Acute Left Ventricular Failure with Pulmonary Edema : Severe dyspnea, orthopnea, bilateral pulmonary crackles, hypoxemia, and S3 gallop.

Renal Damage :

Acute Kidney Injury / Malignant Nephrosclerosis : Rapid escalation of serum creatinine, oliguria, microscopic or gross hematuria, proteinuria, and red blood cell casts resulting from acute arteriolar fibrinoid necrosis.

Ophthalmologic Damage :

Grade III / IV Hypertensive Retinopathy : Retinal flame hemorrhages, cotton-wool spots (microinfarcts), hard lipid exudates ("macular star"), and bilateral papilledema (optic nerve head swelling with blurred disc margins).

Obstetric & Sympathetic Crises :

Eclampsia / Severe Preeclampsia : Blood pressure ≥160/110 mm Hg after 20 weeks gestation accompanied by severe headache, visual scotomas, epigastric/RUQ pain, thrombocytopenia, transaminitis, or generalized tonic-clonic seizures.

Hyperadrenergic States : Pheochromocytoma crisis, cocaine or methamphetamine toxicity, acute withdrawal from centrally acting alpha-2 agonists (clonidine), or monoamine oxidase inhibitor (MAOI) interactions with dietary tyramine.

Management of Hypertensive Urgency

Hypertensive urgency is defined as severe blood pressure elevation (SBP ≥180 and/or DBP ≥120 mm Hg) in a patient who is clinically stable with NO evidence of acute target organ damage .

The Clinical Fallacy of Emergency Department Referral

Patients with hypertensive urgency do not require hospitalization, intensive care admission, or intravenous antihypertensives. Large observational trials have proven that emergency department transfer or rapid blood pressure reduction does not improve cardiovascular outcomes and frequently leads to overt harm. In up to 30% of patients, blood pressure drops by 10 to 20 mm Hg after simply resting quietly in a private room for 30 minutes.

Pathophysiology of Right-Shifted Autoregulation

In patients with chronic long-standing hypertension, vascular remodeling (medial hypertrophy and hyaline arteriolosclerosis) shifts the cerebral and renal vascular autoregulatory curve to the right . While a normotensive brain maintains constant cerebral blood flow across a mean arterial pressure (MAP) range of 60 to 120 mm Hg, a chronically hypertensive brain requires a higher MAP (e.g., 110 to 160 mm Hg) to preserve adequate perfusion. A precipitous decrease in blood pressure drops cerebral perfusion below the lower limit of autoregulation, directly causing cerebral hypoperfusion, watershed ischemic stroke, syncope, or acute tubular necrosis .

Oral Pharmacotherapy & Protocol

Blood pressure in hypertensive urgency should be lowered gradually over 24 to 48 hours using oral agents in an ambulatory outpatient setting:

Oral Amlodipine : 5 to 10 mg PO once daily. Dihydropyridine CCB; smooth, predictable onset with long elimination half-life (30–50 hours).

Oral Labetalol : 100 to 200 mg PO twice daily. Combined alpha-1- and non-selective beta-blocker.

Oral Captopril : 12.5 to 25 mg PO. Short-acting ACE inhibitor with rapid oral onset (15–30 minutes). Avoid in pregnancy, renal artery stenosis, or acute hyperkalemia.

Oral Clonidine : 0.1 to 0.2 mg PO initial dose, followed by 0.1 mg hourly if needed (maximum 0.6 mg). Centrally acting alpha-2-agonist; causes prominent sedation and carries a severe risk of rebound hypertension if discontinued.

Outpatient Follow-Up : Re-evaluate the patient in the outpatient clinic within 2 to 7 days to assess response, adjust maintenance therapy, reinforce dietary sodium restriction, and evaluate medication adherence.

THE BLACK BOX PROHIBITION: Sublingual Nifedipine

Caution

Administering sublingual or bite-and-swallow immediate-release nifedipine is strictly prohibited and violates the standard of care. Sublingual nifedipine produces rapid, uncontrollable arterial vasodilation that triggers catastrophic systemic hypotension, profound reflex sympathetic tachycardia, watershed cerebral infarction, acute myocardial infarction, and fatal cardiovascular collapse.

Management of Hypertensive Emergency: Intensive Care & Pharmacology

Hypertensive emergency mandates immediate admission to an Intensive Care Unit (ICU) and continuous blood pressure monitoring via an indwelling radial arterial catheter (A-line) . Therapy is conducted with titratable, continuous intravenous infusions.

Continuous Intravenous Antihypertensive Formulations

Medication Mechanism of Action IV Dosing Regimen Onset / Duration Clinical Indications & Adverse Effects

Nicardipine (Cardene) Dihydropyridine Ca2+ channel blocker; selective arteriolar vasodilation 5 mg/h IV infusion; titrate by 2.5 mg/h q5–15min to max 15 mg/h Onset: 5–15 min; Duration: 30–60 min First-line in encephalopathy, stroke, renal crisis; preserves cerebral/coronary blood flow; phlebitis at peripheral site

Clevidipine (Cleviprex) Third-generation ultra-short dihydropyridine CCB; arteriolar dilation 1–2 mg/h IV; double q90sec until near target, titrate by 1–2 mg/h q5min (max 16–32 mg/h) Onset: 2–4 min; Duration: 5–15 min Rapid titration; metabolized by blood/tissue esterases; formulated in 20% lipid emulsion (2 kcal/mL; egg/soy allergy contraindication)

Labetalol Combined alpha-1 and non-selective beta-blocker (alpha:beta ratio 1:7 IV) 10–20 mg slow IV bolus over 2 min; repeat 20–80 mg q10min (max 300 mg) or infuse 0.5–2.0 mg/min Onset: 5–10 min; Duration: 3–6 hours First-line in aortic dissection, stroke, eclampsia; avoids reflex tachycardia; avoid in severe asthma, heart block, or acute HFrEF

Esmolol (Brevibloc) Ultra-short-acting cardioselective beta-1-adrenergic blocker Loading dose: 500 mcg/kg over 1 min; maintenance: 50–300 mcg/kg/min Onset: 1–2 min; Duration: 10–20 min Drug of choice in acute aortic dissection; rapidly titratable; esterase metabolism independent of liver/kidney

Sodium Nitroprusside Direct nitric oxide donor; balanced arterial and venous dilation 0.3 to 2.0 mcg/kg/min IV; max 10 mcg/kg/min (limit high dose to <10 min) Onset: Immediate; Duration: 1–2 min Powerful vasodilator; light-sensitive; black box warning for cyanide & thiocyanate toxicity ; causes ICP elevation and intracerebral steal

Fenoldopam (Corlopam) Selective dopamine DA1 receptor agonist; renal vasodilation 0.1 to 1.6 mcg/kg/min continuous IV infusion Onset: 5 min; Duration: 30–60 min Preserves/improves renal blood flow, promotes natriuresis; ideal in acute kidney injury; increases intraocular pressure (avoid in glaucoma)

Phentolamine Non-selective competitive alpha-adrenergic receptor antagonist 5 to 15 mg IV bolus every 5 to 15 minutes as needed Onset: 1–2 min; Duration: 10–30 min Specific antidote for catecholamine crises (pheochromocytoma, cocaine/amphetamine toxicity, clonidine withdrawal)

Hydralazine Direct arteriolar smooth muscle vasodilator 10 to 20 mg IV slow push every 20 to 30 minutes Onset: 10–30 min; Duration: 2–4 hours Unpredictable, delayed onset and prolonged half-life; causes reflex tachycardia; limited to severe preeclampsia / eclampsia

Standard Blood Pressure Reduction Protocol

In standard hypertensive emergencies (e.g., hypertensive encephalopathy, acute renal injury, malignant hypertension), blood pressure must be reduced in a controlled, stepwise manner to avoid organ hypoperfusion: Mean Arterial Pressure (MAP) = Diastolic BP + 1 3 ( Systolic BP − Diastolic BP ) = 2 × DBP + SBP 3 \text{Mean Arterial Pressure (MAP)} = \text{Diastolic BP} + \frac{1}{3}(\text{Systolic BP} - \text{Diastolic BP}) = \frac{2 \times \text{DBP} + \text{SBP}}{3} Mean Arterial Pressure (MAP) = Diastolic BP + 3 1 ​ ( Systolic BP − Diastolic BP ) = 3 2 × DBP + SBP ​

Phase 1 (First Hour) : Reduce Mean Arterial Pressure (MAP) by no more than 20% to 25% (or lower SBP by ~15–20%).

Phase 2 (Hours 2 to 6) : If the patient remains clinically stable with no signs of neurological or myocardial hypoperfusion, reduce blood pressure toward 160/100 to 110 mm Hg .

Phase 3 (Hours 6 to 24–48) : Gradually normalize blood pressure toward normal physiological levels over the subsequent 24 to 48 hours , transitioning seamlessly to oral antihypertensive agents.

Critical Exceptions to Standard Reduction Goals

There are four critical clinical conditions where standard gradual MAP reduction is abandoned in favor of disease-specific emergency protocols: CRITICAL PROTOCOL EXCEPTIONS TO STANDARD MAP REDUCTION

• ┌────────────────────────────────────────────────────────────────────────────────────────┐
• │ 1. ACUTE AORTIC DISSECTION: ULTRA-RAPID EMERGENCY HYPOTENSION │
• │ • Target: SBP <120 mm Hg AND Heart Rate <60 bpm within TWENTY (20) MINUTES │
• │ • Pathophysiology: Aortic shear stress depends on ventricular ejection velocity (dP/dt)│
• │ • CRITICAL RULE: Administer IV Beta-Blocker (Esmolol/Labetalol) FIRST before any │
• │ vasodilator; vasodilators given alone cause reflex tachycardia and extend dissection │
• └────────────────────────────────────────────────────────────────────────────────────────┘
• │
• ┌───────────────────────────────────────────┴────────────────────────────────────────────┐
• │ 2. ACUTE ISCHEMIC STROKE: PERMISSIVE HYPERTENSION │
• │ • Non-Thrombolysis Candidates: Do NOT treat BP unless SBP >220 or DBP >120 mm Hg │
• │ • If >220/120: Cautiously reduce MAP by ~15% over the first 24 hours │
• │ • Thrombolysis (tPA/TNK) / Thrombectomy Candidates: │
• │ - Pre-Treatment Target: Lower BP to <185/110 mm Hg BEFORE administering thrombolytic │
• │ - Post-Treatment Target: Maintain BP strictly <180/105 mm Hg for at least 24 hours │
• │ • Preferred Agents: IV Labetalol (10-20 mg bolus) or IV Nicardipine (5-15 mg/h) │
• └────────────────────────────────────────────────────────────────────────────────────────┘
• │
• ┌───────────────────────────────────────────┴────────────────────────────────────────────┐
• │ 3. ACUTE INTRACEREBRAL HEMORRHAGE (ICH): RAPID SMOOTH SBP REDUCTION │
• │ • Target: SBP 130 to 140 mm Hg (INTERACT-2 / ATACH-2 trials; avoid SBP <130 mm Hg) │
• │ • Prevents hematoma expansion without inducing peri-hematomal ischemic injury │
• └────────────────────────────────────────────────────────────────────────────────────────┘
• │
• ┌───────────────────────────────────────────┴────────────────────────────────────────────┐
• │ 4. ECLAMPSIA & SEVERE PREECLAMPSIA: RAPID MATERNAL-FETAL STABILIZATION │
• │ • Target: Lower SBP to 140–150 mm Hg and DBP to 90–100 mm Hg within 30–60 minutes │
• │ • AVOID DBP <80 mm Hg (preserves uteroplacental perfusion) │
• │ • Preferred Agents: IV Labetalol or IV Hydralazine + IV Magnesium Sulfate (4-6 g bolus)│
• │ • STRICT CONTRAINDICATION: ACE inhibitors, ARBs, Nitroprusside (fetal cyanide toxicity)│
• └────────────────────────────────────────────────────────────────────────────────────────┘
• 1. Acute Aortic Dissection

Target : Reduce systolic blood pressure to <120 mm Hg (or lowest tolerated mean arterial pressure) and heart rate to <60 beats/min within 20 minutes .

Pathophysiology : Dissection propagation is driven by the rate of change of left ventricular pressure rise over time (dP/dt, aortic wall shear stress).

THE DRUG SEQUENCE EXAM RULE : An intravenous beta-blocker ( esmolol or labetalol ) must be initiated BEFORE administering a vasodilator (nicardipine or sodium nitroprusside). Administering a vasodilator alone stimulates baroreceptor-mediated reflex sympathetic activation, causing tachycardia and an acute increase in dP/dt, which will rip open the dissection flap and cause fatal rupture.

2. Acute Ischemic Stroke

Penumbral Protection & Permissive Hypertension : The ischemic brain consists of an unsalvageable central infarction core surrounded by a viable ischemic penumbra. Penumbral tissue lacks vascular autoregulation; its perfusion depends directly on systemic mean arterial pressure through collateral vessels. Lowering blood pressure precipitously collapses collateral blood flow, converting salvageable penumbral brain tissue into dead infarcted brain.

Protocol for Non-Thrombolysis Candidates : Withhold all antihypertensive therapy unless blood pressure exceeds 220/120 mm Hg . If blood pressure exceeds 220/120 mm Hg, gently lower MAP by 15% over the first 24 hours.

Protocol for Thrombolysis (Alteplase/Tenecteplase) Candidates :

Pre-Thrombolysis : Blood pressure must be lowered to <185/110 mm Hg BEFORE initiating thrombolytic therapy. Infusing a thrombolytic at BP ≥185/110 mm Hg carries an unacceptable risk of fatal symptomatic intracranial hemorrhage.

Post-Thrombolysis : Maintain blood pressure strictly <180/105 mm Hg for at least the first 24 hours following thrombolysis.

First-Line Agents : IV Labetalol (10–20 mg IV bolus over 1–2 minutes, may repeat once) or IV Nicardipine infusion (5–15 mg/h).

3. Acute Intracerebral Hemorrhage (ICH)

In acute non-traumatic intracranial hemorrhage with presenting SBP between 150 and 220 mm Hg, guidelines (supported by INTERACT-2 and ATACH-2) recommend rapidly lowering SBP toward 130 to 140 mm Hg within hours to prevent ongoing hematoma expansion, while avoiding drops in SBP <130 mm Hg which can cause renal injury and cerebral ischemia.

4. Eclampsia & Severe Preeclampsia

Target : Lower systolic BP to 140 to 150 mm Hg and diastolic BP to 90 to 100 mm Hg within 30 to 60 minutes. Diastolic BP must not be reduced <80 mm Hg to maintain uteroplacental blood flow.

First-Line Pharmacotherapy : Intravenous Labetalol (20 mg IV bolus, then 40–80 mg every 10–20 min up to 300 mg) or Intravenous Hydralazine (5–10 mg IV slow push over 2 min, repeat in 20 min). Oral immediate-release nifedipine (10–20 mg swallowed whole) is an effective oral alternative.

Seizure Prophylaxis : Concurrently administer Intravenous Magnesium Sulfate (4 to 6 grams IV loading dose over 20 minutes, followed by a continuous infusion of 1 to 2 grams/hour for at least 24 hours postpartum).

Contraindicated in Pregnancy : ACE inhibitors and ARBs (teratogenic, fetal renal dysgenesis), sodium nitroprusside (fetal cyanide poisoning), and loop diuretics (deplete maternal intravascular volume).

Loading diagram... Hypertensive Crisis Diagnostic Triage & Target Organ Decision Algorithm